Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV„ÄÅLarge Borrmann III Type and Bulky N Positive Advanced Gastric Cancer
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.
Immunotherapy|Gastrict Cancer
DRUG: Tislelizumab|DRUG: Apatinib Mesylate|DRUG: oxaliplatin|DRUG: Tegafur
Total/moderate tumor regression rate under pathology, Primary tumor or lymph node surgery specimen pathological examination without residual tumor cell, 4 weeks after surgery
Objective Response Rate (ORR), Objective Response Rate Determine the tumor shrinkage rate, tumor boundary and the adhesion of tumor, At the end of Cycle 3 (each cycle is 21 days)|Overall survival (OS), Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.

Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.

Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up.

Defined from date of Signing ICF to date of first documentation of death from any cause or censored at the date of the last follow-up., every 3 months (up to 24 months) ]
To evaluate the clinical efficacy and safety of Tislelizumab combined with apatinib mesylate, oxaliplatin plus S1.